Drug intelligence / Profile preview

PDS0203

Development stage: Preclinical
Lead developer: PDS Biotech
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

**PDS0203** is an investigational, recombinant protein-subunit COVID-19 vaccine developed by PDS Biotech with Farmacore Biotechnology. It combines a SARS-CoV-2 spike-derived recombinant protein antigen with PDS Biotech's Versamune T-cell-activating platform, aiming to induce neutralizing antibodies as well as durable virus-specific CD4 and CD8 T-cell responses. PDS Biotech currently lists the program as preclinical; Farmacore held Latin American development rights, and Blanver was selected to manufacture and commercialize the candidate in Latin America. ([pdsbiotech.com](https://www.pdsbiotech.com/index.php/pipeline/infectious-disease/pds0203))

Other names: Versamune-CoV2-FCVersamune-CoV-2-FCVersamune-CoV 2-FCVersamune-CoV-2Versamune-CoV2Versamune-CoV 2

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on PDS0203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDS0203.